[go: up one dir, main page]

WO1992008474A3 - Traitement des maladies pulmonaires - Google Patents

Traitement des maladies pulmonaires Download PDF

Info

Publication number
WO1992008474A3
WO1992008474A3 PCT/GB1991/002049 GB9102049W WO9208474A3 WO 1992008474 A3 WO1992008474 A3 WO 1992008474A3 GB 9102049 W GB9102049 W GB 9102049W WO 9208474 A3 WO9208474 A3 WO 9208474A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
provides
cyclosporin
corticosteroids
identified
Prior art date
Application number
PCT/GB1991/002049
Other languages
English (en)
Other versions
WO1992008474A2 (fr
Inventor
Anthony Barry Kay
Neil Christopher Barnes
Peter John Cole
Original Assignee
Nat Heart & Lung Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909025154A external-priority patent/GB9025154D0/en
Application filed by Nat Heart & Lung Inst filed Critical Nat Heart & Lung Inst
Publication of WO1992008474A2 publication Critical patent/WO1992008474A2/fr
Publication of WO1992008474A3 publication Critical patent/WO1992008474A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Le ciblage pharmacologique spécifique des lymphocytes T constitue une nouvelle approche pour le traitement de l´asthme chronique (à la fois chez les patients relativement sensibles aux effets des corticoïdes et chez les patients résistant à leurs effets) et pour le traitement d'autres maladies pulmonaires telles que la bronchestasie et la mucovicidose, ainsi que la sinusite. Dans cette invention, on utilise de la cyclosporine A et d'autres agents immunosuppresseurs suivant le même mode ou lieu d'action ou suivant un mode ou un lieu d'action similaire, pour traiter des maladies se caractérisant par l'obstruction de l'écoulement de l'air et/ou une sinusite chronique. D'autres agents appropriés comprennent le FK 506, la répamicyne et des anticorps anti-CD4 rendus assimilables pour l'homme. Cette invention concerne également un test in vitro permettant de prédire la réponse clinique aux corticoïdes et aux agents immunosuppresseurs. A l'aide du test in vitro on peut détecter la résistance aux corticoïdes et on peut ainsi identifier les patients résistant aux corticoïdes qui peuvent être traités avec de la cyclosporine A ou un autre agent immunosuppresseur approprié.
PCT/GB1991/002049 1990-11-20 1991-11-20 Traitement des maladies pulmonaires WO1992008474A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9025154.7 1990-11-20
GB909025154A GB9025154D0 (en) 1990-11-20 1990-11-20 Treatment of lung diseases
GB9026620.6 1990-12-07
GB909026620A GB9026620D0 (en) 1990-11-20 1990-12-07 Treatment of lung diseases

Publications (2)

Publication Number Publication Date
WO1992008474A2 WO1992008474A2 (fr) 1992-05-29
WO1992008474A3 true WO1992008474A3 (fr) 1992-06-25

Family

ID=26297977

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1991/002049 WO1992008474A2 (fr) 1990-11-20 1991-11-20 Traitement des maladies pulmonaires

Country Status (2)

Country Link
AU (1) AU8910891A (fr)
WO (1) WO1992008474A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US6770279B1 (en) 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
DE69312077T2 (de) * 1992-10-08 1997-10-30 Kennedy Inst Of Rheumatology Behandlung von autoimmun- und entzundungskrankheiten
US5874080A (en) * 1994-03-03 1999-02-23 Genentech, Inc. Anti-IL-8 monoclonal antibodies for treatment of asthma
JP3780315B2 (ja) * 1994-03-03 2006-05-31 ジェネンテク・インコーポレイテッド 炎症性疾患の処置のための抗ｉｌ−８モノクローナル抗体
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
JP3266005B2 (ja) * 1995-09-19 2002-03-18 藤沢薬品工業株式会社 エアゾール製剤およびその製造方法
GB9702944D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
AUPP223198A0 (en) * 1998-03-06 1998-04-02 Fujisawa Pharmaceutical Co., Ltd. New use
WO2000006153A1 (fr) * 1998-07-28 2000-02-10 Smithkline Beecham Corporation Propenamides tenant lieu de modulateurs de ccr5
GB9818278D0 (en) * 1998-08-22 1998-10-14 Smith & Nephew Compositions
DK1159003T3 (da) * 1999-03-02 2011-02-07 Centocor Inc Anti-tnfalfa-antistoffer til terapi af steroid-resistent astma
JP2006517217A (ja) * 2003-02-10 2006-07-20 ノバルティス アクチエンゲゼルシャフト コルチコイドおよび／またはカルシニューリン阻害剤耐性疾患を処置するための、コルチコイドおよび免疫抑制剤を含んでなる医薬組合せ剤
WO2004073614A2 (fr) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Polytherapie servant au traitement de troubles immuno-inflammatoires
EP1675615A1 (fr) * 2003-09-23 2006-07-05 PDL BioPharma, Inc. Traitement de maladies respiratoires avec des anticorps diriges contre le recepteur de l'interleukine-2
EP1699456A1 (fr) * 2003-12-30 2006-09-13 Astellas Pharma Inc. Utilisation de macrolides pour le traitement ou la prevention des obstructions des voies respiratoires
CA2606226A1 (fr) * 2005-04-27 2006-11-02 University Of Florida Research Foundation, Inc. Materiaux et methodes permettant d'ameliorer la degradation de proteines mutantes associees avec une maladie humaine
EP2505058A1 (fr) 2006-03-31 2012-10-03 Medarex, Inc. Animaux transgéniques exprimant des anticorps chimériques pour une utilisation dans la préparation d'anticorps humains
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
CA2705539A1 (fr) 2007-11-13 2009-05-22 Evec Inc. Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Dialog Information Services, file 155, Medline, 66- 92, Dialog Accession No. 06229897, Lagrue G. et al.: "Membranoproliferative glomerulonephritis assosiciated with Buckley's syndrome treated with cyclosporin. Glomerulonephrite membrano-proliferative associee a un syndrome de Buckley traitee par la ciclosporine", & Presse Med Apr 11 1987, 16 (13) p619-21 *
Dialog Information Services, file 155, Medline, 66-92, Dialog Accession No. 07458632, Fukuda T.: "Inhibition of antigen-induced late asthmatic response and bronchial hyperresponsiveness by cyclosporin A", & Arerugi May 1990, & Arerugi May 1990, 39 (5) p483-7 *
Dialog Information Services, file 155, Medline, 66-92, Dialog Accession No. 07590095, Fukuda T. et al: "The role of eosinophils, neutrophils and lymphocytes for the development of bronchial hyperresponsiveness in a guinea pig model of asthma", & Nippon Kyobu Shikkan Gakkai Zasshi Oct 1990, 28 (10)p128 8-93 *
Dialog Information Services, file 155, Medline, 66-92, Dialog Accession No. 07858952, Szczeklik A. et al: "Cyclosporin for steroid-dependentasth ma", & Allergy May 1991, 46 (4) p312-5 *
Dialog Information Services, file 155, Medline, 66-92, Dialog Accession No. 07902257, Fukuda T. et al: "Inhibition of antigen-induced late asthmatic response and bronchial hyperresponsiveness by cyclosporin and FK 506", & Int Arch Allergy Appl Immunol (SWITZERLAND) 1991, 94 (1-4) p259-61 *
Dialog Information Services, file 5, BIOSIS, 69-92, Dialog Accession No. 4856115, Pedersen C. et al.: "Inhibitory effect of cyclosporin A on histamine release from human leukocytes and rat mast cells", & Allergy (COPENH) 40 (2), 1985, 103-107 *
Dialog Information Services, file 5, BIOSIS, 69-92, Dialog Accession No. 7905334, Finnerty N.A. et al.: "Effect of cyclosporine on corticosteroid dependent asthma", & J Allergy Clin Immunol 87 (1 part 2), 1991, 297 *

Also Published As

Publication number Publication date
AU8910891A (en) 1992-06-11
WO1992008474A2 (fr) 1992-05-29

Similar Documents

Publication Publication Date Title
WO1992008474A3 (fr) Traitement des maladies pulmonaires
Epstein et al. Time course of hemosiderin production by alveolar macrophages in a murine model
Wardlaw et al. Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils.
US5837713A (en) Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
Ip et al. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty
JP3434824B2 (ja) 例えばｎ−（３−オキシヘキサノイル）ホモセリンラクトンのような免疫抑制剤及び抗アレルギー性化合物
Fujisawa et al. The neutrophil and chronic allergic inflammation
ITMI912296A0 (it) Nuovi pregna 1,4-diene-3,20.dione-16,17-acetal-21-esteri, procedimento per la loro preparazione, composizione e metodi per il trattamento di stati infiammatori
WO2005099776A3 (fr) Agents limitant les effets steroidiens et methodes d'utilisation associees
RU2004123463A (ru) Стероидные сапогенины и их производные для лечения болезни
CY2009010I1 (el) Μεθοδος για εμπλουτισμο r-επιμερους 16,17-ακεταλης παραγωγων των 21-ακυλοξυ πρεγνα-1,4-διεν-11.βητα., 16.αλφα., 17.αλφα.-τριολ-3,20-διονης
BR9811823A (pt) Método e composições para tratar reações alérgicas de fase tardia e doenças inflamatórias
Patella et al. Protein Fv produced during vital hepatitis is a novel activator of human basophils and mast cells.
Dalakas The role of high-dose immune globulin intravenous in the treatment of dermatomyositis
CA2268305A1 (fr) Utilisation d'un inhibiteur de h+, k+-atpase dans le traitement de polypes du nez
WO2001082953A3 (fr) Methodes de traitement de maladies associees a une inflammation dans le cadre des pathologies non ischemiques
Mehindate et al. Induction of chemokine gene expression by major histocompatibility complex class II ligands in human fibroblast-like synoviocytes. Differential regulation by interleukin-4 and dexamethasone.
Skowron et al. Alternating and intermittent regimens of zidovudine (3′-azido-3′-deoxythymidine) and dideoxycytidine (2′, 3′-dideoxycytidine) in the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex
Aoki et al. Protective effects of a novel nonglucocorticoid 21-aminosteroid (U74006F) during traumatic shock in rats
WO2003103723A3 (fr) Procedes d'imagerie de neutrophiles dans la fibrose kystique
Briggs et al. Plasma lipoprotein changes during oral contraception
Shijubo et al. Eosinophilic cationic protein in chronic eosinophilic pneumonia and eosinophilic granuloma
WO1998041238A3 (fr) Methodes et kits de traitement et de diagnostic de leiomyomes
Robbins et al. Complement component C5 is required for release of alveolar macrophage-derived neutrophil chemotactic activity
Massey et al. Cutaneous IgE‐mediated inflammatory lesion size is inhibited by an H1 antagonist (terfenadine) while mediator release is unaffected in vivo and in vitro

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MC MG MN MW NL NO PL RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MC MG MN MW NL NO PL RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA